3 Top Stock Buybacks – Week of 2/25

Targeting stocks with recently announced buyback programs can be beneficial for investors. Buyback programs can be seen as a signal of confidence by the company’s management in the future prospects of the business. When a company announces a buyback program, it indicates that it believes its stock is undervalued and that it has excess cash available to repurchase shares, which can be interpreted as a positive sign for investors. Buybacks can also potentially increase the value of the remaining shares by reducing the total number of shares outstanding, which could lead to higher earnings per share and potentially higher stock prices.

Here are three stock buybacks for the week –

Golden Heaven Group Holdings Ltd. – SYM: GDHG
Recent Price: $0.48
Buyback Action: The Board of Directors approved a new $6 million share repurchase program, equal to around 26% of its market cap at announcement.
Description: Golden Heaven Group Holdings Ltd., together with its subsidiaries, engages in the management and operation of urban amusement parks, water parks, and complementary recreational facilities in China. Its parks offer a range of recreational experiences, including thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities.

===
NOW is the time to get in on this trillion-dollar megatrend

10 to own

Now is the time to position yourself for the next round of explosive growth from what will soon be a trillion-dollar market. But don’t chase yesterday’s winners! The AI hype is off the charts and some AI stocks have run so far that they are looking WAY overvalued. When they crash back down to earth, some investors could get hurt. I don’t want that to happen to you! So I’m making our new special report on the best AI stocks to own now free for a limited time.

Get it here.

===

PROG Holdings, Inc. – SYM: PRG
Recent Price: $28.09
Buyback Action: The Board of Directors announced that it had approved an additional $302 million stock repurchase agreement. This represents around 20% of its market cap at announcement.
Description: PROG Holdings, Inc., a fintech holding company, provides payment options to consumers. It operates through three segments: Progressive Leasing, Vive, and Four. The company owns Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial, an omnichannel provider of second-look revolving credit products. It also offers Four Technologies, provider of Buy Now, Pay Later payment options through four interest-free installments; and Build, a credit building financial management tool. The company was formerly known as Aaron’s Holdings Company, Inc. and changed its name to PROG Holdings, Inc. in December 2020. PROG Holdings, Inc. was founded in 1955 and is based in Draper, Utah.

===
Top 20 Living Economist Shares the Largest Position in His Personal IRA

Investing legend Dr. Mark Skousen recently gave a talk to a small group in the heart of Washington, D.C. In it, he revealed the cornerstone of his retirement plan – and the one investment that helped make him a millionaire.

Click here to watch Dr. Skousen’s presentation – and learn about “the best way to become a millionaire in America.”

===

Halozyme Therapeutics, Inc. – SYM: HALO
Recent Price: $39.71
Buyback Action: The Board of Directors announced that it had approved a new $750 million stock repurchase agreement. This represents around 15% of its market cap at announcement.
Description: Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

===
Is your retirement account safe?

digital dollar guide

The so-called “cashless trend” is sweeping the globe.

Banks refusing to give people their cash.

Forcing them to use digital money.

Imagine going to your bank.

Only to be told you can’t access the cash in your account.

This is not a fantasy.

It’s happening right now.

A new Free Guide reveals how to escape the coming digital dollar.

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.